CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors, which target the programmed cell death protein‐1 (PD‐1) receptor/PD‐1 ligand 1 (PD‐L1) pathway in order to restore antitumor immunity have demonstrated unprecedented survival outcomes in clinical trials and are now supported by several guidelines for first‐line treatment of stage IV NSCLC.5